The Mpox outbreak has renewed interest in Kenya from various foreign vaccine suppliers. One of the few WHO-approved Mpox ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

MCLEAN, VA / ACCESS Newswire / July 31, 2025 / Gladstone Capital Corporation (Nasdaq:GLAD) announces the following event: ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

A strategy of selecting stocks based on rapid revenue growth has outperformed the broad market over the decades MarketWatch's Brett Arends covered research showing that a combination of looking back ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent. Already registered? If you don't have a login or your ...

HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...

In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the ...

"Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump" was originally created and published by ...

Discover key takeaways from Moderna's Q2 2025 earnings call, including FDA approvals, cost reductions, pipeline strategies, and financial updates.